It is expected that when a new drug is made available it is better than its predecessors in treating its specified condition. However, a new study suggests this may not be the case. Mariam Ujeyl and her colleagues assert in a recent paper that newly approved drugs are rarely better than cheaper alternatives already available. After researching 39 proprietary medicinal products launched in the German market between 2009 and 2010, it was found that there was frequently insufficient data available to prove their increased efficacy when approval was granted. Because there are no legal requirements to directly compare new drugs to their older counterparts, it is generally automatically assumed newer products are better. However, researchers found that for approximately half of the approvals the drug had only been trailed against a placebo and not an effective competitor product. This not only throws into question the pricing of new drugs but the quality of new treatment currently being administered across the globe. Find the nearest Barchester care home.